Another newly discovered biomarker is now under consideration as a tool to help evaluate and treat disease. When the body expresses it, it appears to be tied to better survival chances in both non-small cell lung cancer and head and neck cancer.
Roche's Ventana Medical Systems will work with Denmark's Genmab to come up with a companion diagnostic test to be paired with a targeted anticancer drug now in development.
Foundation Medicine will develop a companion diagnostic test for use with a Clovis Oncology drug now in mid-stage clinical trials to treat patients with ovarian cancer.
Maryland's Personal Genome Diagnostics raised $2.8 million to help advance development of its cancer genome analysis technology. Separately, the company is launching its new METDetect Assay that helps spot alterations in the MET gene in circulating tumor DNA directly from a patient's blood.
International researchers led by Michigan's Beaumont Health System discovered two biomarkers that helped predict resistance to radiation therapy for patient's with squamous cell cancer of the head and neck.
New research supports the use of a circulating tumor cell blood test, rather than the standard PSA biomarker diagnostic, to predict a patient's odds of surviving prostate cancer.
Trovagene made real progress in 2013, launching its urine-based cancer test and expanding or forging collaboration deals with research facilities and diagnostic and pharmaceutical companies. But financial results for the year remained a mixed bag.
The last 24 hours offered an important lesson over just how closely analysts and investors are tracking every movement on the immunotherapy front in cancer R&D.
Biodesix scored itself a CE mark that will help expand access to its personalized lung cancer treatment test, a big milestone in the Colorado outfit's push to bring the product into more widespread use.
Back in 2010, Ariad Pharmaceuticals' ridaforolimus was a promising cancer therapy worth up to $700 million in the eyes of Merck. Now, in light of an FDA rejection and some dimming development prospects, Merck has quietly washed its hands of the drug, handing it back to its former partner.